Details Basic Details Date Tuesday, August 21, 2018 Type Presentation Medical Product dabigatran warfarin Health Outcome(s) acute myocardial infarction (AMI), myocardial infarction Materials Minor Differences, Major Consequences? Lessons Learned from Replication of a Claims-Based Drug Safety Assessment Additional Information Information Host 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Related Assessment(s) Abstracts of the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic, August 22–26, 2018 | Abstract 365 A Protocol for Assessment of Dabigatran and Selected Safety Outcomes Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study Contributors Presenter(s) Ting-Ying Jane Huang, Laura Hou, Laura Shockro, Ella Pestine, Michael Nguyen, Judith C. Maro, Rima Izem